HexahydrocurcuminCAS# 36062-05-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 36062-05-2 | SDF | Download SDF |
| PubChem ID | 73554061 | Appearance | White powder |
| Formula | C21H26O6 | M.Wt | 374.43 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (133.54 mM; Need ultrasonic) | ||
| Chemical Name | 5-hydroxy-1-(4-hydroxy-3-methoxycyclohexyl)-7-(4-hydroxy-3-methoxyphenyl)heptan-3-one | ||
| SMILES | COC1CC(CCC1O)CCC(=O)CC(CCC2=CC(=C(C=C2)O)OC)O | ||
| Standard InChIKey | XMNDMZNXKHJPKM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H32O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h5,9,11,15-16,19,21-22,24-25H,3-4,6-8,10,12-13H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Hexahydrocurcumin has cytotoxic effect, may prove useful in cancer prevention. 2. Hexahydrocurcumin together with 5-fluorouracil exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer. 3. Hexahydrocurcumin is an anti-atherosclerogenic agent in humans, can inhibit platelet aggregation in the treatment of human platelet-rich plasma. 4. Hexahydrocurcumin has in vitro antioxidant and anti-inflammatory activities, it has potential beneficial effects as a food and/or dietary supplement. |
| Targets | PGE | NOS | COX |
Hexahydrocurcumin Dilution Calculator
Hexahydrocurcumin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6707 mL | 13.3536 mL | 26.7073 mL | 53.4145 mL | 66.7682 mL |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3415 mL | 10.6829 mL | 13.3536 mL |
| 10 mM | 0.2671 mL | 1.3354 mL | 2.6707 mL | 5.3415 mL | 6.6768 mL |
| 50 mM | 0.0534 mL | 0.2671 mL | 0.5341 mL | 1.0683 mL | 1.3354 mL |
| 100 mM | 0.0267 mL | 0.1335 mL | 0.2671 mL | 0.5341 mL | 0.6677 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Hexahydrocurcumin is a natural compound which posesses anticancer and anti-inflammatory activities; selective COX-2 inhibitor. IC50 value: Target: in vitro: The relative antioxidant potencies of ginger compounds decreased in similar order of 1-dehydro-[6]-gingerdione, hexahydrocurcumin>6-shogaol>6-dehydroshogaol in both 1,1-diphenyl-2-picyrlhydrazyl (DPPH) radical-scavenging and trolox equivalent antioxidant capacity (TEAC) assays [1]. HHC alone markedly decreased the viability of HT-29 human colon cancer cells compared to control. HHC significantly down-regulates COX-2 mRNA expression compared to the control (control: 100.05% ± 0.03% vs HHC: 61.01% ± 0.35%, P < 0.05) but does not alter COX-1 mRNA. In combined treatment, addition of HHC to a low dose of 5-FU exerts a synergistic effect against the growth of HT-29 cells by markedly reducing cell viability to a greater degree than monotherapy [2]. in vivo: The combined effects of HHC with 5-FU exhibit a synergistic inhibition by decreasing ACF formation mediated by down-regulation of COX-2 expression in rats [3].
References:
[1]. Li F, et al. In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin. Food Chem. 2012 Nov 15;135(2):332-7.
[2]. Srimuangwong K, et al. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012 May 21;18(19):2383-9.
[3]. Srimuangwong K, et al. Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. World J Gastroenterol. 2012 Dec 21;18(47):6951-9.
- Tetrahydrocurcumin
Catalog No.:BCN2724
CAS No.:36062-04-1
- Dihydrosanguinarine
Catalog No.:BCN3713
CAS No.:3606-45-9
- Alpinetin
Catalog No.:BCN5315
CAS No.:36052-37-6
- Diepiserratenediol
Catalog No.:BCN7433
CAS No.:3604-92-0
- Ecdysone
Catalog No.:BCN2629
CAS No.:3604-87-3
- 2',4'-Dihydroxy-6'-methoxyacetophenone
Catalog No.:BCN5314
CAS No.:3602-54-8
- Nandrolone decanoate
Catalog No.:BCC9087
CAS No.:360-70-3
- Glycodeoxycholic acid
Catalog No.:BCN7250
CAS No.:360-65-6
- [Ala17]-MCH
Catalog No.:BCC6024
CAS No.:359784-84-2
- 3,6-Ditigloyloxynortropane
Catalog No.:BCN1877
CAS No.:359723-70-9
- Pterosin G
Catalog No.:BCN8148
CAS No.:35964-50-2
- Triptotin F
Catalog No.:BCN3482
CAS No.:359630-36-7
- Octahydrocurcumin
Catalog No.:BCN2725
CAS No.:36062-07-4
- B-HT 933 dihydrochloride
Catalog No.:BCC7474
CAS No.:36067-72-8
- B-HT 920
Catalog No.:BCC1417
CAS No.:36085-73-1
- Sodium cholate
Catalog No.:BCN6981
CAS No.:361-09-1
- Propranolol glycol
Catalog No.:BCC6817
CAS No.:36112-95-5
- RBC8
Catalog No.:BCC5569
CAS No.:361185-42-4
- 3,4-Secolupa-4(23),20(29)-diene-3,28-dioic acid
Catalog No.:BCN7243
CAS No.:36138-41-7
- Saxagliptin
Catalog No.:BCC3934
CAS No.:361442-04-8
- JDTic
Catalog No.:BCC1670
CAS No.:361444-66-8
- D-(+)-Fucose
Catalog No.:BCN6432
CAS No.:3615-37-0
- alpha-L-Rhamnose
Catalog No.:BCN2592
CAS No.:3615-41-6
- Phytin
Catalog No.:BCN1285
CAS No.:3615-82-5
Inhibitory effect of hexahydrocurcumin on human platelet aggregation.[Pubmed:22908571]
Nat Prod Commun. 2012 Jul;7(7):883-4.
The effects of Hexahydrocurcumin on adenosine diphosphate (ADP)-induced human platelet aggregation were studied. Treatment of human platelet-rich plasma with Hexahydrocurcumin resulted in an inhibitory effect on platelet aggregation, suggesting the potential of this compound as an anti-atherosclerogenic agent in humans.
In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin.[Pubmed:22868095]
Food Chem. 2012 Nov 15;135(2):332-7.
Hexahydrocurcumin, 1-dehydro-[6]-gingerdione, 6-dehydroshogaol and 6-shogaol were evaluated for their antioxidant and anti-inflammatory activities in the present study. The relative antioxidant potencies of ginger compounds decreased in similar order of 1-dehydro-[6]-gingerdione, Hexahydrocurcumin>6-shogaol>6-dehydroshogaol in both 1,1-diphenyl-2-picyrlhydrazyl (DPPH) radical-scavenging and trolox equivalent antioxidant capacity (TEAC) assays. All tested compounds could attenuate lipopolysaccharide (LPS)-elicited increase of prostaglandin E2 (PGE(2)) in murine macrophages (RAW 264.7) in a concentration-dependent manner but Hexahydrocurcumin of 7muM and 6-shogaol of 7muM. The strongest inhibitory effect was observed for 6-dehydroshogaol and 6-shogaol at 14muM with the inhibition of 53.3% and 48.9%, respectively. Furthermore, both 6-dehydroshogaol and 1-dehydro-[6]-gingerdione significantly suppressed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins in a concentration-dependent fashion. These results contribute to our theoretical understanding of the potential beneficial effects of consuming ginger as a food and/or dietary supplement.
Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells.[Pubmed:22654430]
World J Gastroenterol. 2012 May 21;18(19):2383-9.
AIM: To investigate the ability of Hexahydrocurcumin (HHC) to enhance 5-fluorouracil (5-FU) in inhibiting the growth of HT-29 cells by focusing on cyclooxygenase (COX)-2 expression. METHODS: Antiproliferative effects of HHC and 5-FU, alone and in combination, on growth of HT-29 human colon cancer cells were assessed using 5-diphenyltetrazolium bromide (MTT) reduction assay. In combination treatment, low doses of 5-FU were used combined with various concentrations of HHC to minimize the toxicity and side effects of 5-FU. The therapeutic effects of these drugs on down-regulation of COX-2 mRNA and protein expression were examined using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting analysis. RESULTS: MTT reduction assay indicated that HHC alone markedly decreased the viability of HT-29 human colon cancer cells compared to control. Semi-quantitative RT-PCR analysis indicated that HHC is a selective COX-2 inhibitor. This finding was supported by the observation that HHC significantly down-regulates COX-2 mRNA expression compared to the control (control: 100.05% +/- 0.03% vs HHC: 61.01% +/- 0.35%, P < 0.05) but does not alter COX-1 mRNA. In combined treatment, addition of HHC to a low dose of 5-FU exerts a synergistic effect against the growth of HT-29 cells by markedly reducing cell viability to a greater degree than monotherapy. Semi-quantitative RT-PCR indicated that 5-FU at the concentration of 5 mumol/L in combination with HHC at the concentration of 25 mumol/L significantly down-regulates COX-2 mRNA expression when compared with values in cells treated with 5-FU or HHC alone (HHC + 5-FU: 31.93% +/- 5.69%, 5-FU: 100.66% +/- 4.52% vs HHC: 61.01% +/- 0.35%, P < 0.05). CONCLUSION: HHC together with 5-FU exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer.
Cytotoxic activity and cell cycle analysis of hexahydrocurcumin on SW 480 human colorectal cancer cells.[Pubmed:22224285]
Nat Prod Commun. 2011 Nov;6(11):1671-2.
The cytotoxicity of Hexahydrocurcumin and its effect on the cell cycle in human colorectal cancer cells SW480 has been studied for the first time. The compound, extracted from Zingiber officinale, was shown to be cytotoxic to colorectal cancer cells. Treatment of SW480 cells with Hexahydrocurcumin (100 microM) resulted in a massive accumulation of the cells in the G1/G0 phase of the cell cycle. The cytotoxic effect of Hexahydrocurcumin may prove useful in cancer prevention.
